Both produce sustained, dose-dependent increases in both GH and IGF-1 without significantly altering other pituitary hormones such as prolactin, FSH, LH, or TSH
IGF-1 LR3 Insulin-like growth factor 1 Long R3 (IGF-1 LR3) is a peptide that plays a critical role in muscle development and growth
It has potent effects of antioxidant, anti-inflammatory, anti-angiogenesis, and anti-cancer [131]
DO NOT spray the water directly onto the lyophilized powder cake
Key Highlights Three once-monthly injections achieved placebo-adjusted weight loss of up to 6.3% at Week 12, increasing to 7.5% at Week 16 Weight loss maintained up to 4 months after the final dose, supporting once-quarterly maintenance therapy potential No weekly lead-in dosing required, differentiating ASC30 from many current GLP-1 regimens Safety profile consistent with the GLP-1 class, with mild-to-moderate adverse events and no discontinuations Why It Matters: Convenience advantage: Monthly or quarterly dosing could significantly improve adherence vs weekly GLP-1 injections Small-molecule innovation: ASC30 is a GLP-1 biased small molecule, enabling both oral and injectable formulations Platform validation: Supports Ascletis Ultra-Long-Acting Platform (ULAP) for developing long-duration metabolic therapies Key Takeaway: ASC30 highlights the next frontier in obesity therapeuticsultra-long-acting incretin therapies
